Topical Progesterone

Menopause

Volumn 10, Issue 4, 2003, Pages 374-377

  Lee, John R ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; PROGESTERONE;

BLOOD; BREAST TUMOR; CHEMISTRY; DRUG EFFECT; ENDOMETRIUM; FEMALE; HUMAN; INTRADERMAL DRUG ADMINISTRATION; NOTE; POSTMENOPAUSE; SALIVA;

ADMINISTRATION, CUTANEOUS; BREAST NEOPLASMS; ENDOMETRIUM; ESTRADIOL; FEMALE; HUMANS; POSTMENOPAUSE; PROGESTERONE; SALIVA;

EID: 0141559197     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/00042192-200310040-00018     Document Type: Letter

References (5)

1. Chang K-J, Lee TTY, Linares-Cruz G, Fournier S, de Lignieres B. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in viv. Fertility & Sterility 1995; 63:785-791.
2. Foidart J-M, Colin C, Denoo X, Desroux, et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertility & Sterility 1998; 69:963-969.
3. Cummings SR, Browner WS, Bauer D, Stone K, et al. Endogenous hormones and the risk of hip and vertebral fracture among older women. N Engl J Med 1998; 339:733-738.
4. Cummings SR, Tu Duong MA, Kenyon E, Cauley JA, Whitehead M, Krueger KA. Serum estradiol level and risk of breast cancer during treatment with roloxifene. JAMA 2002; 287:216-220.
5. Anasti JN, Leonetti HB, Wilson KJ. Topical progesterone cream has antiproliferative effect on estrogen-stimulated endometrium. Obstet Gynecol 2001; 97(Suppl 4):S10.